Ergebnis der Suchanfrage nach Therapie

Orte

Alle 19 Treffer anzeigenweniger anzeigen

Oberspier Teheran Ternopil Tespe Thale Theene Themar Thiersee Torrance

Inhalte

Neueste Relevanteste

Filtern

365 Treffer

31.03.2008 – 17:19
Wirtschaft
Boehringer Ingelheim
Landmark Trial ONTARGET(R) Proves Telmisartan is as Protective as Ramipril and Better Tolerated in a Broad High-Risk Cardiovascular Population. From ONTARGET(R) it May be Concluded That Telmisartan can Prevent Every 5th Serious Cardiovascular Event
Ingelheim, Germany (ots/PRNewswire) - - Results of 25,620 Patient Study ONTARGET(R) (ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial) Presented Today at the 57th Annual Scientific Session of the American College of Cardiology(1) - For Non-US Healthcare Media The results of the ...
mehr
25.10.2007 – 14:09
Wirtschaft
Boehringer Ingelheim
New Three-Year Data Confirms Aptivus(R) (tipranavir) as Effective and Durable Treatment Option for Treatment-Experienced Patients
Madrid, Spain (ots/PRNewswire) - - For Non-U.S. Media New data from the combined RESIST studies (RESIST-1 and RESIST-2) show that Aptivus(R) (tipranavir), used with Norvir (ritonavir), provides a superior and durable treatment response for up to three years in treatment- experienced HIV patients versus ...
mehr
06.09.2007 – 09:05
Wirtschaft
Boehringer Ingelheim
Boehringer Ingelheim to Initiate First Phase III Pivotal Study for New Oncology Compound BIBW 2992(i)
Ingelheim, Germany (ots/PRNewswire) - - New Data on BIBW 2992(i), a Potent, Irreversible, Second-Generation Oral Signal Transduction Inhibitor Provides Glimpse of Next Chapter in Lung Cancer Care - For Non-US Media Boehringer Ingelheim announced today from the 12th World Conference on Lung Cancer (WCLC) that the company plans to commence Phase III ...
mehr
04.09.2007 – 16:30
Panorama
Boehringer Ingelheim
Prehospital Thrombolysis for AMI to be Studied in New Clinical Trial / Study will investigate concept that prehospital lysis can be at least as good as primary PCI
Ingelheim, Germany (ots) - For scientific media outside the USA, Canada and Japan Boehringer Ingelheim announced today that it is undertaking a new initiative in the treatment of heart attack (ST-segment elevation myocardial infarction or STEMI). The company will sponsor a new clinical trial known as ...
mehr
03.09.2007 – 10:04
Wirtschaft
Boehringer Ingelheim
Suffering in Silence - The Real Impact of the Last Taboo
Ingelheim, Germany (ots/PRNewswire) - Constipation is a condition that we are all familiar with, however, according to new international research from Dulcolax(R), constipation actually affects much more than just bowel movements and can have a severely detrimental impact on people's quality of life, in some cases comparable to that experienced by people suffering from more serious ailments. The Dulcolax(R) survey ...
mehr
25.07.2007 – 03:03
Finanzen
Boehringer Ingelheim
Data Presented at International AIDS Society (IAS) Conference Shows Long-Term Viramune(R) (nevirapine) Efficacy and Increase in Good Cholesterol
Sydney, Australia (ots/PRNewswire) - New data from two new studies of Viramune(R) (nevirapine) were presented at the 4th International AIDS Society (IAS) in Sydney, Australia. Results from an extended three-year follow-up analysis of the 2NN study demonstrated that HIV-positive patients taking ...
mehr
24.07.2007 – 08:05
Wirtschaft
Boehringer Ingelheim
Boehringer Ingelheim Announces First International Head-to-Head Trial of Aptivus(R) (tipranavir) versus darunavir in Treatment-Experienced HIV-Positive Patients
Ingelheim, Germany (ots/PRNewswire) - - Trial to compare newest protease inhibitors in treatment-experienced patients with resistance to more than one PI Boehringer Ingelheim GmbH announced today that enrollment of the POTENT study will begin in August 2007. POTENT will compare the efficacy and safety ...
mehr
23.07.2007 – 06:51
Wirtschaft
Boehringer Ingelheim
European Survey to Gain Insight into Treatment-Experienced Patients' Perspectives on Living with HIV
Sydney, Australia (ots/PRNewswire) - Recent launches of new protease inhibitors and the anticipated availability of new antiretroviral drug classes have increased the therapeutic options available to treatment-experienced HIV-positive patients, and made achieving an undetectable viral load a realistic goal ...
mehr
23.07.2007 – 03:45
Wirtschaft
Boehringer Ingelheim
International Experts and Women Living With HIV Discuss Urgent Needs of HIV-Positive Women at International AIDS Society (IAS) Congress
Sydney, Australia (ots/PRNewswire) - - Panelists Available For Interviews - For Immediate Release: Webcast Will Be Available At: Http://Link.Viostream.Com/?A02deceb-Ecf4-4d9f-9118-F5f60faef629 Women Living Positive, a roundtable discussion at the IAS congress in Sydney, featured the ...
mehr
18.06.2007 – 10:03
Wirtschaft
Boehringer Ingelheim
More Than Half of Hypertensive Patients Remain Uncontrolled and at Higher Risk of Heart Attack and Stroke - Telmisartan May Decrease This Risk
Milan, Italy (ots/PRNewswire) - - For non-US Healthcare Media - Results From Two Large, Multinational, Practice-Based Observational Studies in Blood Pressure New data announced today at the Annual European Society of Hypertension (ESH) show that measuring blood pressure in a doctor's office alone does ...
mehr
14.06.2007 – 14:11
Wirtschaft
Boehringer Ingelheim
Boehringer Ingelheim Initiates SPRING Study of Aptivus(R) (tipranavir) in Diverse Group of Highly Treatment-Experienced HIV-Positive Patients
Ingelheim, Germany (ots/PRNewswire) - Boehringer Ingelheim GmbH announced today that it has begun to enroll patients in the SPRING study. The SPRING study will be one of the largest racially and gender diverse international studies of highly treatment-experienced HIV-1 infected patients. The trial ...
mehr
10.05.2007 – 07:04
Wirtschaft
Boehringer Ingelheim
Boehringer Ingelheim Initiates International Head-to-Head HIV/AIDS Trial
Ingelheim, Germany (ots/PRNewswire) - - Trial to Compare Efficacy and Safety of Viramune(R) (Nevirapine) Versus Atazanavir/Ritonavir in Treatment-Naive Patients Boehringer Ingelheim GmbH announced today that it has initiated and begun enrollment of patients in the ArTEN trial, which will compare the efficacy and safety of Viramune(R) (nevirapine), ...
mehr
31.01.2007 – 09:10
Wirtschaft
Boehringer Ingelheim
Data Published in AIDS Show Viramune(R) (nevirapine) Achieves Durable Benefit in Switch Patients
Ingelheim, Germany (ots/PRNewswire) - Long-term data from the Nevirapine/Efavirenz/Abacavir (NEFA) study demonstrate that patients who switched from a protease inhibitor-based regimen to a non-nucleoside reverse transcriptase inhibitor-based regimen containing Viramune(R) (nevirapine) or efavirenz achieved comparable efficacy and safety to their previous regimen ...
mehr
15.11.2006 – 08:05
Wirtschaft
Boehringer Ingelheim
Long-Term Data Show Aptivus(R) (tipranavir) Continues to Outperform Group of Protease Inhibitors in RESIST Trials
Glasgow, Scotland, November 15 (ots/PRNewswire) - - New Sub-analyses Provide Insight into Treatment Benefits New data from the combined RESIST studies (RESIST-1 and RESIST-2) show that Aptivus(R) (tipranavir), used with ritonavir (tipranavir/r) as part of combination antiretroviral therapy, continued to ...
mehr
31.10.2006 – 08:32
Wirtschaft
Boehringer Ingelheim
Boehringer Ingelheim's Pramipexole (Mirapexin(R)/Sifrol(R)) Shown to Improve Depressive and Motivational Symptoms in Parkinson's Disease
Kyoto, Japan (ots/PRNewswire) - - Further Therapeutic Potential of Pramipexole to be Investigated in New Disease-Modification Trial - For non-US Healthcare Media New data presented today from a meta-analysis* of nearly 1,300 Parkinson's disease (PD) patients indicate that pramipexole (Mirapexin(R) ...
mehr
05.09.2006 – 08:00
Panorama
Boehringer Ingelheim
Boehringer Ingelheim's pramipexole (Sifrol(R)/Mirapexin(R)) Can Provide Benefit of Improved Mood Disturbance for People With Restless Legs Syndrome
GLASGOW, Scotland (ots) - - FOR HEALTHCARE JOURNALISTS (For media outside the US only) - New Data Shows pramipexole is an Effective Treatment Option for the Broad Range of RLS Symptoms During Both the Night and Daytime New data indicate that when treated with ...
mehr
14.08.2006 – 17:04
Wirtschaft
Boehringer Ingelheim
Tipranavir Achieves Virologic and Immunologic Improvements in HIV-Positive Children at 48-Weeks of Therapy
Toronto (ots/PRNewswire) - New data on tipranavir oral solution from a Phase II dose finding study in 115 HIV-1 infected children aged 2 to 18 years were announced today at the 16th International AIDS Conference (IAC) in Toronto, Canada. Results from this 48-week analysis show that patients achieved virologic ...
mehr
22.05.2006 – 06:04
Wirtschaft
Boehringer Ingelheim
New Evidence Validates Global Prevalence and Severity of Abdominal Cramping and Pain
Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Professional and Consumer Journalists - Not for Distribution to USA Media - Survey Shows 25% of World's Population Suffer From Common and Distressing Ailment That can be Effectively Treated New data presented at the premier international gastroenterology congress Digestive Disease Week (DDW) 2006 ...
mehr
24.02.2006 – 10:05
Wirtschaft
Boehringer Ingelheim
Boehringer Ingelheim Receives Recommendation From EU Scientific Committee for Sifrol(R)/ Mirapexin(R) (Pramipexole) for the Treatment of Restless Legs Syndrome (RLS)
Ingelheim, Germany (ots/PRNewswire) - - For Non-US Healthcare Professional Media Boehringer Ingelheim announced today that that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of Sifrol(R) / Mirapexin(R) ...
mehr
21.11.2005 – 10:05
Finanzen
Boehringer Ingelheim
New Data Demonstrate Efficacy of Two Leading Anti-HIV Treatments
Dublin, Ireland, November 21 (ots/PRNewswire) - - New hope for HIV/AIDS patients: APTIVUS(R) outperforms several commonly prescribed drugs in the protease inhibitor (PI) class DUBLIN, Ireland, November 21 /PRNewswire/ -- - Experts Emphasize Need for Effective Therapy in Response to Increased Prevalence of HIV/AIDS throughout Europe At the 10th European AIDS Clinical Society (EACS) conference, experts ...
mehr
21.11.2005 – 10:04
Finanzen
Boehringer Ingelheim
APTIVUS(R) Sustains Convincing Anti-HIV Effect Through 48 Weeks
Dublin, Ireland, November 21 (ots/PRNewswire) - - Additional Data Provide Further Guidance on Maximizing Treatment Response with APTIVUS(R) New data presented at the 10th European AIDS Conference (EACS) in Dublin demonstrate that through 48 weeks, APTIVUS(R) (tipranavir) provides a convincing and durable benefit, achieving and maintaining a superior treatment response in patients with resistant HIV.(1) ...
mehr
28.07.2005 – 15:53
Wirtschaft
Boehringer Ingelheim
Positive Opinion in Europe for Tipranavir
Rio De Janeiro, Brazil and Ingelheim, Germany (ots/PRNewswire) - - New Data Support its Use as Powerful Treatment Against HIV Drug Resistance RIO DE JANEIRO, Brazil and INGELHEIM, Germany, July 28 /PRNewswire/ -- Boehringer Ingelheim announced today that the CHMP (Committee for Medicinal Products for Human Use) in London has issued a positive opinion for tipranavir, a non-peptidic protease inhibitor, to ...
mehr
23.06.2005 – 13:53
Wirtschaft
Boehringer Ingelheim
U.S. FDA Approves New Anti-HIV Drug Aptivus(R) for Use in Combination Therapy
Ridgefield, Connecticut (ots/PRNewswire) - - The Following Press Release Was Issued By Our U.S. Affiliate Boehringer Ingelheim Pharmaceuticals, Inc. in The United States on June 23, 2005 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Aptivus(R) (tipranavir) ...
mehr
28.02.2005 – 08:03
Finanzen
Boehringer Ingelheim
Efficacy of Investigational Anti-HIV Agent Tipranavir Demonstrated by New Data
INGELHEIM, Germany,, February 28 (ots/PRNewswire) - - Tipranavir/r More Effective Than Lopinavir/r in Large-Scale Studies of Treatment-Experienced HIV-Positive Patients New data from multiple analyses presented last week at the 12th Conference on Retroviruses and Opportunistic Infections support the efficacy of the investigational non-peptidic protease ...
mehr
18.11.2004 – 12:25
Wirtschaft
Boehringer Ingelheim
Boehringer Ingelheim Announces 24-Week Results From Second Phase III Pivotal Study of Tipranavir
Glasgow, Scotland, November 18 (ots/PRNewswire) - - RESIST-2 Data Demonstrate Efficacy in Treatment-Experienced Patient Population New tipranavir pivotal Phase III data show that a statistically significant higher percentage of treatment-experienced HIV-positive patients taking tipranavir therapy achieved treatment response versus those taking other ...
mehr
01.11.2004 – 14:14
Wirtschaft
Boehringer Ingelheim
Boehringer Ingelheim Announces 24-Week Interim Results from Tipranavir RESIST-1 Phase 3 Study
Washington, November 1 (ots/PRNewswire) - New data from a pivotal Phase 3 study (RESIST-1) demonstrate that a statistically significant greater percentage of HIV-positive patients taking a tipranavir-based regimen achieved a treatment response versus those taking a regimen containing one of several marketed protease inhibitors (PIs). Treatment response in this study ...
mehr
25.10.2004 – 08:04
Wirtschaft
Boehringer Ingelheim
Boehringer Ingelheim Submits Marketing Authorisation Application to European Union and to the FDA for Investigational Anti-HIV Agent Tipranavir
Ingelheim, Germany (ots/PRNewswire) - Boehringer Ingelheim today announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for tipranavir. Simultaneously the documentation was submitted to the FDA. Tipranavir is a non-peptidic protease inhibitor (NPPI) for ...
mehr
04.05.2004 – 08:03
Finanzen
Medigene AG
euro adhoc: MediGene AG / MediGene's First Drug Eligard® Is Launched (E)
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Martinsried - San Diego, May 4, 2004. Eligard®, the first drug of the German-American biotechnology company MediGene AG (Frankfurt, Prime Standard: MDG), is available in German pharmacies today. With the launch of the prescription drug to treat ...
mehr
25.02.2004 – 09:13
Finanzen
Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG reports Fourth Quarter and Full Year Results 2003
Bad Homburg, Germany (ots) - Summary Full Year 2003: Company met or exceeded financial targets for 2003 and will propose 7th consecutive dividend increase Net Revenues $ 5,528 million + 9% Operating income (EBIT) $ 757 million + 9% Net income $ 331 million + 14% Operating Cash Flow $ ...
mehr
02.12.2003 – 07:33
Finanzen
Medigene AG
euro adhoc: MediGene AG / MediGene Receives Approval for Anti-cancer Drug LeuprogelÒ (Eligard®) First drug approval for a German biotechnology company (E)
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Martinsried - San Diego, December 2, 2003: As the first German biotechnology company, MediGene AG (Frankfurt, Prime Standard: MDG) has received marketing authorization for a drug. The ...
mehr

Vorherige45678910111213Nächste

Ergebnis der Suchanfrage nach Therapie

Orte

Themen

Inhalte